Epilepsy | Treatment Algorithms | Claims Data Analysis | US | 2020

Epilepsy is a heterogeneous condition requiring individualized treatment—especially for patients who are persistently refractory to treatment. Neurologists consider many factors when selecting among the numerous first-, second-, and third-generation antiepileptic drugs (AEDs) currently available, and they must make adjustments throughout a patient’s disease course to achieve optimal seizure control. Understanding the evolving patient journey in epilepsy provides important context about the complex, saturated, and heavily generic drug market that developers of new AED brands will enter. Based on national patient-level claims data, this report explores the use of key therapies in both newly diagnosed and recently treated patients, examines line of therapy progression, and assesses persistence and compliance by brand.

QUESTIONS ANSWERED

  •  What patient shares do standard-of-care AEDs and newer brands garner by line of therapy in newly diagnosed patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed epilepsy patients?
  • How have Briviact, Vimpat, Epidiolex, and other third-generation brands been integrated into the treatment algorithm, and what is their source of business?
  • What percentage of epilepsy patients receive drug therapy within two years of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within two years of diagnosis?
  • What percentage of epilepsy patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

Markets covered: United States.

Real-world data: Longitudinal patient-level claims data analysis.

Key companies: GW Pharmaceuticals, Eisai, Supernus Pharmaceuticals, Upsher-Smith, UCB, Sunovion, Pfizer.

Key drugs covered: Vimpat, Aptiom, Briviact, Epidiolex, Fycompa, Lyrica, levetiracetam, lamotrigine, carbamazepine and oxcarbazepine, valproates.

Key analysis provided:

  • Brand/therapy usage across a longitudinal patient sample.
  • Newly diagnosed patient analysis.
  • Treatment initiation and progression.
  • Line of therapy analysis.
  • Combination therapy analysis.
  • Source of business for recently treated patients.
  • Persistency and compliance analysis.
  • Product-level patient flowchart.

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.